Stuti Pant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stuti Pant has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Montaldo
Centre for Perinatal Neuroscience, Department of Paediatrics, Imperial College London, London, UK
4 shared publications Sudhin Thayyil
Medicine, Imperial College London, London, UK
4 shared publications- Maria Moreno Morales
Imperial College of Science Technology and Medicine, London, UK
3 shared publications - Prathik Bandiya
Indira Gandhi Institute of Child Health
3 shared publications - Reema Garegrat
Imperial College London, London, UK
3 shared publications - Seetha Shankaran
Pediatrics (Neonatology), The University of Texas at Austin, Austin, Texas, USA
3 shared publications
Latest Publications
- 28 October 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Feasibility of neurodevelopmental outcome assessments after early and extended erythropoietin monotherapy for neonatal encephalopathy in low- and middle-income countries: an external pilot randomised controlled trial
Objective To assess the feasibility of a randomised controlled trial of early erythropoietin (Epo) therapy with neurodevelopmental follow-up. Design Multicentre, double-blind, external pilot randomised controlled trial. Setting Eight tertiary neonatal units in India and Bangladesh that were part of the Consortium for Time-Critical Neuroprotection Trials in Neonatal Encephalopathy (CONNECTIONS). Patients 50 infants (≥36 weeks) with moderate or severe hypoxic-ischaemic encephalopathy (HIE). Interventions Infants were randomised to Epo 500 U/kg/day for nine doses (n=26) or sham (n=24) within 6 hours of birth. Therapeutic hypothermia was not allowed. Main outcome measures Feasibility of recruitment, protocol adherence, timing of intervention delivery, MRI acquisition and completion of assessment at 18–22 months using the Bayley Scales of Infant and Toddler Development, fourth edition, scales of infant and toddler development. Results Among 50 infants, 45 (90%) had moderate HIE and 5 (10%) had severe HIE, and the trial intervention was given at a mean (SD) age of 4.4 (1.2) hours. Adherence to the trial protocol was excellent. All 33 infants who survived beyond a week had MRI scans which were abnormal in 30 (91%). Overall, 16 (32%) died before hospital discharge, 21 (42%) before 18 to 22 months; 29 (58%) met the composite outcome of death or moderate to severe disability with a 100% follow-up. All four infants discharged against medical advice subsequently died. Conclusions Robust research governance, early erythropoietin administration in infants with HIE, MRI acquisition and complete neurodevelopmental follow-up can be achieved in South Asian neonatal units. CONNECTIONS provides a platform for high-quality multicountry randomised controlled trials. Trial registration number NCT05395195.
- 28 October 2026
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Feasibility of neurodevelopmental outcome assessments after early and extended erythropoietin monotherapy for neonatal encephalopathy in low- and middle-income countries: an external pilot randomised controlled trial
Objective To assess the feasibility of a randomised controlled trial of early erythropoietin (Epo) therapy with neurodevelopmental follow-up. Design Multicentre, double-blind, external pilot randomised controlled trial. Setting Eight tertiary neonatal units in India and Bangladesh that were part of the Consortium for Time-Critical Neuroprotection Trials in Neonatal Encephalopathy (CONNECTIONS). Patients 50 infants (≥36 weeks) with moderate or severe hypoxic-ischaemic encephalopathy (HIE). Interventions Infants were randomised to Epo 500 U/kg/day for nine doses (n=26) or sham (n=24) within 6 hours of birth. Therapeutic hypothermia was not allowed. Main outcome measures Feasibility of recruitment, protocol adherence, timing of intervention delivery, MRI acquisition and completion of assessment at 18–22 months using the Bayley Scales of Infant and Toddler Development, fourth edition, scales of infant and toddler development. Results Among 50 infants, 45 (90%) had moderate HIE and 5 (10%) had severe HIE, and the trial intervention was given at a mean (SD) age of 4.4 (1.2) hours. Adherence to the trial protocol was excellent. All 33 infants who survived beyond a week had MRI scans which were abnormal in 30 (91%). Overall, 16 (32%) died before hospital discharge, 21 (42%) before 18 to 22 months; 29 (58%) met the composite outcome of death or moderate to severe disability with a 100% follow-up. All four infants discharged against medical advice subsequently died. Conclusions Robust research governance, early erythropoietin administration in infants with HIE, MRI acquisition and complete neurodevelopmental follow-up can be achieved in South Asian neonatal units. CONNECTIONS provides a platform for high-quality multicountry randomised controlled trials. Trial registration number NCT05395195.
- Open Access
- 29 April 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004247
Lived experiences of healthcare personnel in supporting parents around neonatal death: encounters, challenges and meaning
Objective: To explore healthcare personnel’s (HCP) lived experiences of caring for dying newborns and supporting bereaved parents in neonatal intensive care unit (NICU), drawing on relational, ethical and organisational factors. Design: Qualitative study using hermeneutic phenomenology. Semistructured, in-depth interviews analysed thematically to interpret the meanings embedded in participants’ narratives. Setting: Three tertiary NICUs in the UK. Participants: Eight female HCP (five nurses, three doctors) with 3–20 years’ (median=12 years) NICU experience. Results: Experiences were strongly shaped by temporality and clinical trajectory. Expected deaths (gradual decline) enabled preparation, continuity of carer and opportunities for closeness and memory-making, whereas unexpected deaths (sudden deterioration) heightened moral distress, complicated communication and constrained what could be offered to families. Four themes described how optimal experiences were pursued: (1) facilitating parent–infant closeness, (2) providing comprehensive family support, (3) communication and interpersonal engagement and (4) an emotionally intense experience for HCPs. The study revealed an overarching phenomenon— creating an optimal experience for parents as an implicit coping mechanism for HCP. As they cared for a dying newborn and its family, it helped them achieve a sense of accomplishment as well as the strength to power through the distress and anguish. Conclusions: The study highlights the relational foundation of neonatal end-of-life care, showing that HCPs’ well-being and quality of parental support and care provided are closely linked. Recognising this interdependence may inform training, supervision and organisational design to strengthen compassionate and sustainable NICU bereavement care.
- 29 April 2026
- Published by BMJ in BMJ Paediatrics Open
- Vol. 10 (1) , e004247
Open AccessLived experiences of healthcare personnel in supporting parents around neonatal death: encounters, challenges and meaning
Objective: To explore healthcare personnel’s (HCP) lived experiences of caring for dying newborns and supporting bereaved parents in neonatal intensive care unit (NICU), drawing on relational, ethical and organisational factors. Design: Qualitative study using hermeneutic phenomenology. Semistructured, in-depth interviews analysed thematically to interpret the meanings embedded in participants’ narratives. Setting: Three tertiary NICUs in the UK. Participants: Eight female HCP (five nurses, three doctors) with 3–20 years’ (median=12 years) NICU experience. Results: Experiences were strongly shaped by temporality and clinical trajectory. Expected deaths (gradual decline) enabled preparation, continuity of carer and opportunities for closeness and memory-making, whereas unexpected deaths (sudden deterioration) heightened moral distress, complicated communication and constrained what could be offered to families. Four themes described how optimal experiences were pursued: (1) facilitating parent–infant closeness, (2) providing comprehensive family support, (3) communication and interpersonal engagement and (4) an emotionally intense experience for HCPs. The study revealed an overarching phenomenon— creating an optimal experience for parents as an implicit coping mechanism for HCP. As they cared for a dying newborn and its family, it helped them achieve a sense of accomplishment as well as the strength to power through the distress and anguish. Conclusions: The study highlights the relational foundation of neonatal end-of-life care, showing that HCPs’ well-being and quality of parental support and care provided are closely linked. Recognising this interdependence may inform training, supervision and organisational design to strengthen compassionate and sustainable NICU bereavement care.
- Open Access
- 10 May 2024
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 109 (6) , 594-601
Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial
Objective To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design Double-blind pilot randomised controlled trial. Setting Eight neonatal units in South Asia. Patients Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number NCT05395195.
- 10 May 2024
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 109 (6) , 594-601
Open AccessEarly and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy: a multicentre double-blind pilot randomised controlled trial
Objective To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design Double-blind pilot randomised controlled trial. Setting Eight neonatal units in South Asia. Patients Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number NCT05395195.
- Open Access
- 1 May 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (5) , e2312152
Whole-Body Hypothermia, Cerebral Magnetic Resonance Biomarkers, and Outcomes in Neonates With Moderate or Severe Hypoxic-Ischemic Encephalopathy Born at Tertiary Care Centers vs Other Facilities
Importance: The association between place of birth and hypothermic neuroprotection after hypoxic-ischemic encephalopathy (HIE) in low- and middle-income countries (LMICs) is unknown.Objective: To ascertain the association between place of birth and the efficacy of whole-body hypothermia for protection against brain injury measured by magnetic resonance (MR) biomarkers among neonates born at a tertiary care center (inborn) or other facilities (outborn).Design, Setting, and Participants: This nested cohort study within a randomized clinical trial involved neonates at 7 tertiary neonatal intensive care units in India, Sri Lanka, and Bangladesh between August 15, 2015, and February 15, 2019. A total of 408 neonates born at or after 36 weeks’ gestation with moderate or severe HIE were randomized to receive whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C; hypothermia group) for 72 hours or no whole-body hypothermia (rectal temperatures maintained between 36.0 °C and 37.0 °C; control group) within 6 hours of birth, with follow-up until September 27, 2020.Exposure: 3T MR imaging, MR spectroscopy, and diffusion tensor imaging.Main Outcomes and Measures: ThalamicN-acetyl aspartate (NAA) mmol/kg wet weight, thalamic lactate to NAA peak area ratios, brain injury scores, and white matter fractional anisotropy at 1 to 2 weeks and death or moderate or severe disability at 18 to 22 months.Results: Among 408 neonates, the mean (SD) gestational age was 38.7 (1.3) weeks; 267 (65.4%) were male. A total of 123 neonates were inborn and 285 were outborn. Inborn neonates were smaller (mean [SD], 2.8 [0.5] kg vs 2.9 [0.4] kg;P = .02), more likely to have instrumental or cesarean deliveries (43.1% vs 24.7%;P = .01), and more likely to be intubated at birth (78.9% vs 29.1%;P = .001) than outborn neonates, although the rate of severe HIE was not different (23.6% vs 17.9%;P = .22). Magnetic resonance data from 267 neonates (80 inborn and 187 outborn) were analyzed. In the hypothermia vs control groups, the mean (SD) thalamic NAA levels were 8.04 (1.98) vs 8.31 (1.13) among inborn neonates (odds ratio [OR], −0.28; 95% CI, −1.62 to 1.07;P = .68) and 8.03 (1.89) vs 7.99 (1.72) among outborn neonates (OR, 0.05; 95% CI, −0.62 to 0.71;P = .89); the median (IQR) thalamic lactate to NAA peak area ratios were 0.13 (0.10-0.20) vs 0.12 (0.09-0.18) among inborn neonates (OR, 1.02; 95% CI, 0.96-1.08;P = .59) and 0.14 (0.11-0.20) vs 0.14 (0.10-0.17) among outborn neonates (OR, 1.03; 95% CI, 0.98-1.09;P = .18). There was no difference in brain injury scores or white matter fractional anisotropy between the hypothermia and control groups among inborn or outborn neonates. Whole-body hypothermia was not associated with reductions in death or disability, either among 123 inborn neonates (hypothermia vs control group: 34 neonates [58.6%] vs 34 [56.7%]; risk ratio, 1.03; 95% CI, 0.76-1.41), or 285 outborn neonates (hypothermia vs control group: 64 neonates [46.7%] vs 60 [43.2%]; risk ratio, 1.08; 95% CI, 0.83-1.41).Conclusions and Relevance: In this nested cohort study, whole-body hypothermia was not associated with reductions in brain injury after HIE among neonates in South Asia, irrespective of place of birth. These findings do not support the use of whole-body hypothermia for HIE among neonates in LMICs.Trial Registration: ClinicalTrials.gov Identifier:NCT02387385
- 1 May 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (5) , e2312152
Open AccessWhole-Body Hypothermia, Cerebral Magnetic Resonance Biomarkers, and Outcomes in Neonates With Moderate or Severe Hypoxic-Ischemic Encephalopathy Born at Tertiary Care Centers vs Other Facilities
Importance: The association between place of birth and hypothermic neuroprotection after hypoxic-ischemic encephalopathy (HIE) in low- and middle-income countries (LMICs) is unknown.Objective: To ascertain the association between place of birth and the efficacy of whole-body hypothermia for protection against brain injury measured by magnetic resonance (MR) biomarkers among neonates born at a tertiary care center (inborn) or other facilities (outborn).Design, Setting, and Participants: This nested cohort study within a randomized clinical trial involved neonates at 7 tertiary neonatal intensive care units in India, Sri Lanka, and Bangladesh between August 15, 2015, and February 15, 2019. A total of 408 neonates born at or after 36 weeks’ gestation with moderate or severe HIE were randomized to receive whole-body hypothermia (reduction of rectal temperatures to between 33.0 °C and 34.0 °C; hypothermia group) for 72 hours or no whole-body hypothermia (rectal temperatures maintained between 36.0 °C and 37.0 °C; control group) within 6 hours of birth, with follow-up until September 27, 2020.Exposure: 3T MR imaging, MR spectroscopy, and diffusion tensor imaging.Main Outcomes and Measures: ThalamicN-acetyl aspartate (NAA) mmol/kg wet weight, thalamic lactate to NAA peak area ratios, brain injury scores, and white matter fractional anisotropy at 1 to 2 weeks and death or moderate or severe disability at 18 to 22 months.Results: Among 408 neonates, the mean (SD) gestational age was 38.7 (1.3) weeks; 267 (65.4%) were male. A total of 123 neonates were inborn and 285 were outborn. Inborn neonates were smaller (mean [SD], 2.8 [0.5] kg vs 2.9 [0.4] kg;P = .02), more likely to have instrumental or cesarean deliveries (43.1% vs 24.7%;P = .01), and more likely to be intubated at birth (78.9% vs 29.1%;P = .001) than outborn neonates, although the rate of severe HIE was not different (23.6% vs 17.9%;P = .22). Magnetic resonance data from 267 neonates (80 inborn and 187 outborn) were analyzed. In the hypothermia vs control groups, the mean (SD) thalamic NAA levels were 8.04 (1.98) vs 8.31 (1.13) among inborn neonates (odds ratio [OR], −0.28; 95% CI, −1.62 to 1.07;P = .68) and 8.03 (1.89) vs 7.99 (1.72) among outborn neonates (OR, 0.05; 95% CI, −0.62 to 0.71;P = .89); the median (IQR) thalamic lactate to NAA peak area ratios were 0.13 (0.10-0.20) vs 0.12 (0.09-0.18) among inborn neonates (OR, 1.02; 95% CI, 0.96-1.08;P = .59) and 0.14 (0.11-0.20) vs 0.14 (0.10-0.17) among outborn neonates (OR, 1.03; 95% CI, 0.98-1.09;P = .18). There was no difference in brain injury scores or white matter fractional anisotropy between the hypothermia and control groups among inborn or outborn neonates. Whole-body hypothermia was not associated with reductions in death or disability, either among 123 inborn neonates (hypothermia vs control group: 34 neonates [58.6%] vs 34 [56.7%]; risk ratio, 1.03; 95% CI, 0.76-1.41), or 285 outborn neonates (hypothermia vs control group: 64 neonates [46.7%] vs 60 [43.2%]; risk ratio, 1.08; 95% CI, 0.83-1.41).Conclusions and Relevance: In this nested cohort study, whole-body hypothermia was not associated with reductions in brain injury after HIE among neonates in South Asia, irrespective of place of birth. These findings do not support the use of whole-body hypothermia for HIE among neonates in LMICs.Trial Registration: ClinicalTrials.gov Identifier:NCT02387385
- Open Access
- 18 June 2021
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (3) , 274-278
Ethical Issues around Death and Withdrawal of Life Support in Neonatal Intensive Care
Amongst all the traumatic experiences in a human life, death of child is considered the most painful, and has profound and lasting impact on the life of parents. The experience is even more complex when the death occurs within a neonatal intensive care unit, particularly in situations where there have been conflicts associated with decisions regarding the redirection of life-sustaining treatments. In the absence of national guidelines and legal backing, clinicians are faced with a dilemma of whether to prolong life-sustaining therapy even in the most brain-injured infants or allow a discharge against medical advice. Societal customs, vagaries, and lack of bereavement support further complicate the experience for parents belonging to lower socio-economic classes. The present review explores the ethical dilemmas around neonatal death faced by professionals in India, and suggests some ways forward.
- 18 June 2021
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 89 (3) , 274-278
Open AccessEthical Issues around Death and Withdrawal of Life Support in Neonatal Intensive Care
Amongst all the traumatic experiences in a human life, death of child is considered the most painful, and has profound and lasting impact on the life of parents. The experience is even more complex when the death occurs within a neonatal intensive care unit, particularly in situations where there have been conflicts associated with decisions regarding the redirection of life-sustaining treatments. In the absence of national guidelines and legal backing, clinicians are faced with a dilemma of whether to prolong life-sustaining therapy even in the most brain-injured infants or allow a discharge against medical advice. Societal customs, vagaries, and lack of bereavement support further complicate the experience for parents belonging to lower socio-economic classes. The present review explores the ethical dilemmas around neonatal death faced by professionals in India, and suggests some ways forward.
- Open Access
- 21 May 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (5) , e005757
Parental and professional perceptions of informed consent and participation in a time-critical neonatal trial: a mixed-methods study in India, Sri Lanka and Bangladesh
Introduction Time-critical neonatal trials in low-and-middle-income countries (LMICs) raise several ethical issues. Using a qualitative-dominant mixed-methods design, we explored informed consent process in Hypothermia for encephalopathy in low and middle-income countries (HELIX) trial conducted in India, Sri Lanka and Bangladesh. Methods Term infants with neonatal encephalopathy, aged less than 6 hours, were randomly allocated to cooling therapy or usual care, following informed parental consent. The consenting process was audio-video (A-V) recorded in all cases. We analysed A-V records of the consent process using a 5-point Likert scale on three parameters—empathy, information and autonomy. In addition, we used exploratory observation method to capture relevant aspects of consent process and discussions between parents and professionals. Finally, we conducted in-depth interviews with a subgroup of 20 parents and 15 healthcare professionals. A thematic analysis was performed on the observations of A-V records and on the interview transcripts. Results A total of 294 A-V records of the HELIX trial were analysed. Median (IQR) score for empathy, information and autonomy was 5 (0), 5 (1) and 5 (1), respectively. However, thematic analysis suggested that the consenting was a ceremonial process; and parental decision to participate was based on unreserved trust in the treating doctors, therapeutic misconception and access to an expensive treatment free of cost. Most parents did not understand the concept of a clinical trial nor the nature of the intervention. Professionals showed a strong bias towards cooling therapy and reported time constraints and explaining to multiple family members as key challenges. Conclusion Despite rigorous research governance and consent process, parental decisions were heavily influenced by situational incapacity and a trust in doctors to make the right decision on their behalf. Further research is required to identify culturally and context-appropriate strategies for informed trial participation.
- 21 May 2021
- Published by BMJ in BMJ Global Health
- Vol. 6 (5) , e005757
Open AccessParental and professional perceptions of informed consent and participation in a time-critical neonatal trial: a mixed-methods study in India, Sri Lanka and Bangladesh
Introduction Time-critical neonatal trials in low-and-middle-income countries (LMICs) raise several ethical issues. Using a qualitative-dominant mixed-methods design, we explored informed consent process in Hypothermia for encephalopathy in low and middle-income countries (HELIX) trial conducted in India, Sri Lanka and Bangladesh. Methods Term infants with neonatal encephalopathy, aged less than 6 hours, were randomly allocated to cooling therapy or usual care, following informed parental consent. The consenting process was audio-video (A-V) recorded in all cases. We analysed A-V records of the consent process using a 5-point Likert scale on three parameters—empathy, information and autonomy. In addition, we used exploratory observation method to capture relevant aspects of consent process and discussions between parents and professionals. Finally, we conducted in-depth interviews with a subgroup of 20 parents and 15 healthcare professionals. A thematic analysis was performed on the observations of A-V records and on the interview transcripts. Results A total of 294 A-V records of the HELIX trial were analysed. Median (IQR) score for empathy, information and autonomy was 5 (0), 5 (1) and 5 (1), respectively. However, thematic analysis suggested that the consenting was a ceremonial process; and parental decision to participate was based on unreserved trust in the treating doctors, therapeutic misconception and access to an expensive treatment free of cost. Most parents did not understand the concept of a clinical trial nor the nature of the intervention. Professionals showed a strong bias towards cooling therapy and reported time constraints and explaining to multiple family members as key challenges. Conclusion Despite rigorous research governance and consent process, parental decisions were heavily influenced by situational incapacity and a trust in doctors to make the right decision on their behalf. Further research is required to identify culturally and context-appropriate strategies for informed trial participation.
- Open Access
- 5 May 2021
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 106 (6) , 669-672
Association of Total Sarnat Score with brain injury and neurodevelopmental outcomes after neonatal encephalopathy
We examined the association of Total Sarnat Score (TSS) with brain injury on neonatal magnetic resonance (MR) and adverse neurodevelopmental outcome (NDO) (death or moderate or severe disability) at 2 years of age in 145 infants undergoing therapeutic hypothermia for neonatal encephalopathy. TSS was associated with basal ganglia/thalamic injury on conventional MR (p=0.03) and thalamic N-acetyl aspartate on MR spectroscopy (R2=0.16, p=0.004) at 2 weeks of age, and Bayley Composite Cognitive (R2=0.18, p=0.01), Motor (R2=0.15, p=0.02) and Language (R2=0.11, p=0.01) Scores at 2 years of age after adjustment for seizures at the time of neurological assessment. The accuracy of TSS (area under the curve (AUC)=0.71) for predicting adverse NDO was similar to the modified Sarnat staging (AUC=0.72). TSS of >12 within 6 hours of birth indicated high risk of adverse NDO, while TSS of <4 indicated intact survival and was reassuring of a good outcome among cooled infants.
- 5 May 2021
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 106 (6) , 669-672
Open AccessAssociation of Total Sarnat Score with brain injury and neurodevelopmental outcomes after neonatal encephalopathy
We examined the association of Total Sarnat Score (TSS) with brain injury on neonatal magnetic resonance (MR) and adverse neurodevelopmental outcome (NDO) (death or moderate or severe disability) at 2 years of age in 145 infants undergoing therapeutic hypothermia for neonatal encephalopathy. TSS was associated with basal ganglia/thalamic injury on conventional MR (p=0.03) and thalamic N-acetyl aspartate on MR spectroscopy (R2=0.16, p=0.004) at 2 weeks of age, and Bayley Composite Cognitive (R2=0.18, p=0.01), Motor (R2=0.15, p=0.02) and Language (R2=0.11, p=0.01) Scores at 2 years of age after adjustment for seizures at the time of neurological assessment. The accuracy of TSS (area under the curve (AUC)=0.71) for predicting adverse NDO was similar to the modified Sarnat staging (AUC=0.72). TSS of >12 within 6 hours of birth indicated high risk of adverse NDO, while TSS of <4 indicated intact survival and was reassuring of a good outcome among cooled infants.